Featured Research

from universities, journals, and other organizations

Longer treatment for male urinary tract infection not associated with reduced early or late recurrence risk

Date:
December 3, 2012
Source:
JAMA and Archives Journals
Summary:
A study of more than 33,000 outpatient male veterans suggests that a longer duration of antimicrobial treatment of more than seven days for a urinary tract infection appeared not to be associated with a reduced risk of early or late recurrence compared to a shorter duration (seven days or less) of treatment.

A study of more than 33,000 outpatient male veterans suggests that a longer duration of antimicrobial treatment of more than seven days for a urinary tract infection (UTI) appeared not to be associated with a reduced risk of early or late recurrence compared to a shorter duration (seven days or less) of treatment, according to a report published Online First by Archives of Internal Medicine, a JAMA Network publication.

Related Articles


The optimal treatment duration for UTI in ambulatory, noncatheterized women is well defined, but the optimal treatment duration in men is unknown. Duration of antimicrobial treatment is important because an insufficient treatment duration can lead to recurrent disease, but prolonged treatment can increase costs, promote antimicrobrial resistance and increase the risk of Clostridium difficile infection (CDI, which can be contracted after prolonged use of antibiotics), according to the study background.

Dimitri M. Drekonja, M.D., M.S., and colleagues with the Minneapolis Veterans Affairs Health Care System, Minnesota, used administrative data from the Veterans Affairs Computerized Patient Record System to evaluate treatment patterns for male UTI among outpatients and to assess the association between treatment duration and outcomes, including UTI recurrence and CDI.

Researchers identified 39,149 UTI episodes involving 33,336 unique patients, including 33,336 index cases (85.2 percent), 1,772 early recurrences (4.5 percent) and 4,041 late recurrences (10.3 percent), according to the study results. Patients had an average age of 68 years.

"We found that two drugs (ciprofloxacin and trimethoprim-sulfamethoxazole) were used to treat most male UTI episodes and that the treatment duration varied substantially within the recommended seven to 14 days (84.4 percent of patients) and outside of this range (15.6 percent of patients). Most important, compared with shorter-duration treatment (≤7 days), longer-duration treatment (>7 days) exhibited no association with a reduced risk for early or late recurrence," the authors comment.

Of the index UTI cases, 4.1 percent were followed by early recurrence and 9.9 percent by late recurrence. While longer-duration of treatment was not associated with a reduction in early or late recurrence, it was associated with increased late recurrence compared with shorter-duration treatment (10.8 percent vs. 8.4 percent). Also, C difficile infection risk was higher with longer-duration vs. shorter-duration treatment (0.5 percent vs. 0.3 percent), according to the study results.

Researchers suggest their findings "question the role" of longer-duration treatment for male UTI in the outpatient setting.

"A randomized trial is needed to directly assess the benefits and harms of shorter-duration vs. longer-duration treatment for male UTI," the authors conclude.

Research Letter: Preoperative Urine Cultures at a Veterans Affairs Medical Center

In a related research letter, Dimitri M. Drekonja, M.D., M.S., of the Minneapolis Veterans Affairs Health Care System, Minnesota, and colleagues suggest that preoperative cultures (UCs) of urine are ordered inconsistently and that treatment of preoperative bacteriuria appears to be associated with no benefit, based on a review of medical records for patients undergoing 1,934 cardiothoracic, orthopedic and vascular procedures (Online First).

Commentary: New Perspectives on Urinary Tract Infection in Men

In an accompanying commentary, Barbara W. Trautner, M.D., Ph.D., of the Michael E. DeBakey Veterans Affairs Medical Center, Baylor College of Medicine, Houston, Texas, writes: "Most studies on the treatment of acute urinary tract infection (UTI) in outpatients have been performed in women, usually premenopausal women."

"What both studies can do, and indeed do effectively, is to call into question current treatment practices concerning bacteriuria in men," Trautner continues. "We recommend a culture shift in antibiotic prescribing practices for men with bacteriuria from 'more is better' to 'less is more.' Widespread antimicrobial resistance, appreciation of the human microbiome, outbreaks of CDI [Clostridium difficile infection], and emphasis on cost-effective care discourage the indiscriminate use of antibiotics."

"On the other hand, the studies commented on herein encourage more judicious use of antibiotics by failing to find evidence of clinical benefit with longer courses of antibiotics or with additional courses of preoperative antibiotics. As we continue to explore UTI in the male half of the population, these articles are a timely reminder that standard practice is not always best practice and that critical thinking is required to recognize the difference," Trautner concludes.


Story Source:

The above story is based on materials provided by JAMA and Archives Journals. Note: Materials may be edited for content and length.


Journal References:

  1. Drekonja DM, Rector TS, Cutting A, Johnson JR. Urinary Tract Infection in Male Veterans: Treatment Patterns and Outcomes. Archives of Internal Medicine, 2012; DOI: 10.1001/2013.jamainternmed.829
  2. Drekonja DM, Zarmbinski B, Johnson JR. Preoperative Urine Cultures at a Veterans Affairs Medical Center. Archives of Internal Medicine, 2012; DOI: 10.1001/2013.jamainternmed.834
  3. Trautner BW. ew Perspectives on Urinary Tract Infection in Men. Archives of Internal Medicine, 2012; DOI: 10.1001/jamainternmed.2013.1783

Cite This Page:

JAMA and Archives Journals. "Longer treatment for male urinary tract infection not associated with reduced early or late recurrence risk." ScienceDaily. ScienceDaily, 3 December 2012. <www.sciencedaily.com/releases/2012/12/121203163432.htm>.
JAMA and Archives Journals. (2012, December 3). Longer treatment for male urinary tract infection not associated with reduced early or late recurrence risk. ScienceDaily. Retrieved November 28, 2014 from www.sciencedaily.com/releases/2012/12/121203163432.htm
JAMA and Archives Journals. "Longer treatment for male urinary tract infection not associated with reduced early or late recurrence risk." ScienceDaily. www.sciencedaily.com/releases/2012/12/121203163432.htm (accessed November 28, 2014).

Share This


More From ScienceDaily



More Health & Medicine News

Friday, November 28, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Rural India's Low-Cost Sanitary Pad Revolution

Rural India's Low-Cost Sanitary Pad Revolution

AFP (Nov. 28, 2014) — One man hopes his invention -– a machine that produces cheap sanitary pads –- will help empower Indian women. Duration: 01:51 Video provided by AFP
Powered by NewsLook.com
Research on Bats Could Help Develop Drugs Against Ebola

Research on Bats Could Help Develop Drugs Against Ebola

AFP (Nov. 28, 2014) — In Africa's only biosafety level 4 laboratory, scientists have been carrying out experiments on bats to understand how virus like Ebola are being transmitted, and how some of them resist to it. Duration: 01:18 Video provided by AFP
Powered by NewsLook.com
Ebola Leaves Orphans Alone in Sierra Leone

Ebola Leaves Orphans Alone in Sierra Leone

AFP (Nov. 27, 2014) — The Ebola epidemic sweeping Sierra Leone is having a profound effect on the country's children, many of whom have been left without any family members to support them. Duration: 01:02 Video provided by AFP
Powered by NewsLook.com
Experimental Ebola Vaccine Shows Promise In Human Trial

Experimental Ebola Vaccine Shows Promise In Human Trial

Newsy (Nov. 27, 2014) — A recent test of a prototype Ebola vaccine generated an immune response to the disease in subjects. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins